诺诚健华又一款大药,“正在研究测算”国谈

健识局
17 Jun

几乎踩着医保谈判的时间截止线,诺诚健华CD19单抗坦昔妥单抗姗姗来迟。5月21日,国家药监局批准了坦昔妥单抗联合来那度胺,用于治疗不适合自体造血干细胞移植的复发/难治性弥漫性大B细胞淋巴瘤成人患者。CD19不是一个陌生靶点,在血液肿瘤领域的CAR-T产品中发展最为成熟,但开发单抗的并没有多少。目前,全球CD19单抗不超过十款,国内市场上的基本全靠引进。诺诚健华的坦昔妥单抗是2021年8月从...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10